By Fineline Cube 
China-based Shanghai Escugen has partnered with Spain-headquartered SunRock Biopharma, S.L. to co – develop SRB123, a first – in – class antibody – drug conjugate (ADC) targeting C – C motif chemokine receptor 9 (CCR9). This receptor is overexpressed in multiple solid tumors, including pancreatic, ovarian, and lung cancers.
Partnership and Technology Integration
The collaboration combines SunRock’s proprietary SRB1 antibody with Escugen’s EZWi – Fit linker – payload platform. The goal is to develop a highly differentiated candidate tailored for CCR9 – high, high – internalization solid tumors.
Cooperation Framework
Under the agreement, the two companies filed a joint patent application last year and secured mutual licensing options. The primary objective of the collaboration is to generate robust preclinical proof – of – concept data to support the early clinical development of SRB123.-Fineline Info & Tech